$0.87 -0.03 (%) Peregrine Pharmaceuticals Inc - NASDAQ

Feb. 5, 2016 | 04:00 PM

Partner Headlines

  1. Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab

    Benzinga | Jan. 6, 2016 | 08:12AM EST
  2. New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma

    Benzinga | Nov. 9, 2015 | 08:05AM EST
  3. New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression

    Benzinga | Sep. 8, 2015 | 08:17AM EST
  4. US Stock Futures Tumble, China's Shanghai Plunges 8.5%

    Benzinga | Aug. 24, 2015 | 07:28AM EST
  5. AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

    Benzinga | Aug. 24, 2015 | 04:27AM EST
  6. Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab

    Benzinga | Jun. 25, 2015 | 08:30AM EST
  7. Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting

    Benzinga | Apr. 14, 2015 | 08:02AM EST
  8. Morning Market Gainers

    Benzinga | Feb. 9, 2015 | 09:48AM EST
  9. Monday Morning Movers: Achillion Up, Regulus Down Following Drug Results

    Benzinga | Feb. 9, 2015 | 09:05AM EST
  10. Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib ...

    GuruFocus | Jan. 16, 2015 | 11:02AM EST
  11. Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory ...

    GuruFocus | Dec. 12, 2014 | 11:03AM EST
  12. Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity

    GuruFocus | Dec. 10, 2014 | 11:04AM EST
  13. Avid Bioservices Announces Expansion Of cGMP Manufacturing Capacity

    Benzinga | Dec. 10, 2014 | 08:09AM EST
  14. Earnings Scheduled For December 10, 2014

    Benzinga | Dec. 10, 2014 | 04:53AM EST
  15. Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of ...

    GuruFocus | Nov. 10, 2014 | 11:02AM EST
  16. Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 ...

    GuruFocus | Nov. 7, 2014 | 11:03AM EST
  17. Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From ...

    GuruFocus | Oct. 30, 2014 | 12:03PM EST
  18. Morning Market Movers

    Benzinga | Oct. 15, 2014 | 09:48AM EST
  19. Earnings Scheduled For September 9, 2014

    Benzinga | Sep. 9, 2014 | 05:24AM EST
  20. Earnings Scheduled For July 14, 2014

    Benzinga | Jul. 14, 2014 | 05:33AM EST
  21. Peregrine Pharmaceuticals Announces Investigator-Sponsored Trial Combining Immunotherapy Bavituximab, Ipilimumab

    Benzinga | Apr. 23, 2014 | 07:31AM EST
  22. UPDATE: Peregrine Pharma Reports Data on Bavituximab Presented at AACR Validates Immune-Stimulatory Mechanism of Action

    Benzinga | Apr. 9, 2014 | 11:05AM EST
  23. Morning Market Movers

    Benzinga | Apr. 7, 2014 | 09:40AM EST
  24. Mid Morning Gainers for March 11th, 2014

    Benzinga | Mar. 11, 2014 | 11:20AM EST
  25. Mid-Afternoon Market Update: 3D Printing Names Take a Hit From Barron's Piece as Fuel Cell Names Continue Rally

    Benzinga | Mar. 10, 2014 | 15:50PM EST
  26. Mid-Day Market Update: Chiquita Gains On Merger News; Cliffs Natural Shares Drop

    Benzinga | Mar. 10, 2014 | 12:44PM EST
  27. Mid-Morning Market Update: Markets Open Lower; McDonald's Comparable Sales Fall 0.3%

    Benzinga | Mar. 10, 2014 | 10:35AM EST
  28. Earnings Scheduled For March 7, 2014

    Benzinga | Mar. 7, 2014 | 04:58AM EST
  29. Morning Market Movers

    Benzinga | Jan. 6, 2014 | 09:57AM EST
  30. Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

    Benzinga | Dec. 30, 2013 | 07:37AM EST
  31. Earnings Scheduled For December 10, 2013

    Benzinga | Dec. 10, 2013 | 05:14AM EST
  32. Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields Enhanced Anti-Tumor Activity in Pre-Clinical Model of Melanoma

    Benzinga | Nov. 8, 2013 | 09:10AM EST
  33. Peregrine Pharma Reports Results from Phase 2 Trial of Bavituximab, Says Topline Demonstrates Signs of Anti-Tumor Activity

    Benzinga | Feb. 13, 2013 | 01:36AM EST
  34. Peregrine Pharmaceuticals Finds Its Stride Again: Exclusive Interview With MLV & Co's George Zavoico

    Benzinga | Jan. 25, 2013 | 06:56AM EST
  35. Peregrine Pharmaceuticals Soars 80% on Study Review

    Benzinga | Jan. 8, 2013 | 00:28AM EST
  36. Major Averages Record Small Losses to Start Week

    Benzinga | Jan. 7, 2013 | 09:45AM EST
  37. Morning Market Movers

    Benzinga | Jan. 7, 2013 | 02:48AM EST
  38. Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

    Benzinga | Dec. 11, 2012 | 08:03AM EST
  39. Earnings Scheduled For December 10, 2012

    Benzinga | Dec. 9, 2012 | 19:02PM EST
  40. The Week Ahead: Washington in Focus

    Benzinga | Dec. 7, 2012 | 09:37AM EST
  41. Ballots Are In: Worst CEO in the Biotech Industry Is . . .

    YCharts | Dec. 7, 2012 | 03:49AM EST
  42. Peregrine Shares Higher as Co. Reports Significant Progress in Advancing Cotara Program Into Pivotal Phase III Trial

    Benzinga | Dec. 5, 2012 | 02:19AM EST
  43. Benzinga's Microcap Movers for Wednesday October 17, 2012

    Benzinga | Oct. 17, 2012 | 14:07PM EST
  44. Milberg LLP Announces Pendency of Class Action Lawsuits Filed Against Peregrine Pharmaceuticals

    Benzinga | Oct. 5, 2012 | 09:03AM EST
  45. Benzinga Mid-Day Market Update

    Benzinga | Sep. 26, 2012 | 08:20AM EST
  46. Bronstein, Gewirtz & Grossman Announces Investigation of Peregrine Pharmaceuticals

    Benzinga | Sep. 25, 2012 | 02:33AM EST
  47. Benzinga Mid-Afternoon Market Update

    Benzinga | Sep. 24, 2012 | 09:51AM EST
  48. Mid-Day Market Losers

    Benzinga | Sep. 24, 2012 | 07:04AM EST
  49. Benzinga Mid-Day Market Update

    Benzinga | Sep. 24, 2012 | 06:58AM EST
  50. Morning Market Losers

    Benzinga | Sep. 24, 2012 | 05:08AM EST
Trading Center